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Pulp necrosis of immature permanent teeth can occur from a variety of causes, 
and this condition presents challenges from both an endodontic and restorative 
perspective. Affecting up to 35% of the global population, untreated dental caries in 
permanent teeth is the most prevalent modern health condition.1 If the carious lesion 
progresses to involve the pulp, bacteria and bacterial products cause pulp 
inflammation and eventually infect the pulp space and cause pulp necrosis.2 Similarly, 
certain dental anomalies or trauma to the permanent dentition, which has been 
estimated to occur in 17.5% of children and adolescents, can also cause pulp necrosis 
of immature permanent teeth.3, 4 Immature teeth with necrotic pulps present 
difficulties with cleaning and shaping due to thin dentinal walls, and obturation can be 
difficult due to large canals and incompletely formed apices.5 These teeth are also at 
higher risk of fracture or tooth loss due to incomplete dentin deposition and root 
formation.6 
Infected immature permanent teeth diagnosed with pulp necrosis were 
historically treated by apexification with long-term application calcium hydroxide 
(Ca(OH)2) to induce formation of a hard tissue barrier at the tooth apex.7 This 
procedure has a high reported success rate, but it also has significant disadvantages.8 
The long-term placement of calcium hydroxide has been reported to significantly 
weaken radicular dentin, and the procedure also requires high patient compliance and 
recall ability.9, 10 A more modern approach to apexification is the technique of using 
bioceramics. This technique also has a high reported success and is advantageous 
compared to calcium hydroxide because it can be performed in as few as a single 
3 
visit; however, it still fails to address weakened tooth structure due to incomplete 
development of the pulp-dentin complex.8, 11, 12 
Due to the disadvantages of apexification, regenerative endodontic procedures 
(REPs) were developed with the goal of regenerating the pulp-dentin complex and 
continuing development of the tooth roots in both length and width of dentin. If 
continued root development can occur, then the lack of tooth strength associated with 
apexification can be overcome. In spite of the successes of REPs, there are still 
challenges to ideal clinical outcomes.13 Numerous studies have reported cases 
including minimal continued root development, empty root canal space after a REP 
procedure, lack of a normal pulp histology, or re-infection following REPs.14-18 Due 
to these complications of REPs, tissue engineering with stem cells, scaffolds, and 
growth factors have become prominent research areas concerning REPs.19 
 
REGENERATIVE ENDODONTIC PROCEDURES 
The first step in endodontic regeneration is to address the intraradicular 
infection. Because immature teeth with necrotic pulps have thin walls, disinfection of 
the root canal space relies predominantly on irrigation and the placement of 
medicaments instead of mechanical instrumentation.20 Calcium hydroxide is 
commonly used in endodontics as an intracanal medicament, especially in cases 
involving trauma to the dentition.21, 22 Calcium hydroxide has been recommended as a 
standard medicament for regenerative endodontics due to its antibacterial activity as 
well as its biocompatibility with stem cells of relevance to regenerative 
endodontics.14, 22 Other antibiotic mixtures such as DAP (ciprofloxacin and 
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metronidazole) and TAP (ciprofloxacin, metronidazole, and minocycline) have also 
been used as a substitute intracanal medicament for calcium hydroxide.23 
Three general components are required for tissue regeneration: reparative 
cells, a scaffold that allows for cell growth, and bioactive molecules to guide and 
stimulate the reparative cells.24 An induced blood clot is the most commonly used 
scaffold for REPs, but there are a wide variety of scaffolds that researchers have used 
in an attempt to optimize outcomes of REPs.25 Collagen-based scaffolds, platelet-rich 
fibrin, and even nanofibrous scaffolds loaded with antibiotics have been investigated 
for clinical use.25, 26 Bioactive molecules, such as growth factors and cytokines, can 
be released from the blood clot as well as from dentin.24 Dentin is an important 
consideration in regenerative endodontics because it is a tissue to be regenerated, and 
it is also the surface upon which all intracanal treatments directly contact. Dentin is 
composed of a 70% mineral phase, 20% organic matrix, and 10% water by volume.27 
Instead of being considered as an inert structural material, dentin harbors many 
growth factors such as insulin-like growth factor, transforming growth factor beta, 
and skeletal growth factor.28, 29 
 
STEM CELLS 
Much research has been conducted in the application of mesenchymal dental 
stem cells for tissue regeneration. Dental pulp stem cells are multipotent cells that can 
proliferate extensively and form cells of all three germ layers, and these cells can be 
further divided based on their niche location and particular properties.30, 31 Two dental 
stem cell lines of particular importance in endodontic regeneration are stem cells from 
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the apical papilla (SCAPs) and dental pulp stem cells (DPSCs).32 Previous research 
has shown that DPSCs are capable of forming a pulp-like vascularized tissue 
surrounded by odontoblast-like cells and mineralized tissue resembling dentin in mice 
models.33 For the current study, human DPSCs were used because of their relevance 
in endodontic regeneration, and these cells can be differentiated into the osteogenic 
lineage. 
 
PYK2 ACTIVITY IN OSTEOGENESIS 
The FAK family of kinases, which consist of the proline-rich tyrosine kinase 2 
(Pyk2) and the focal adhesion kinase (FAK), play a critical role in integrin-mediated 
cell adhesion and cytoskeletal dynamics.34 Pyk2 and FAK are cytoplasmic non-
receptor tyrosine kinases that function in cell migration, polarization, proliferation 
and cell survival.34-36 FAK and Pyk2 signaling can be activated by cytokines 
(interleukins), growth factors (TNF-α, TGF-β), and microRNAs.37 Increased 
activation and expression of FAK and Pyk2 has been found in a variety of human 
cancers, and overexpression of Pyk2 in cancerous tissues has been correlated with 
poorer outcomes.34, 37 
Pyk2 is expressed in a wide variety of cell types including the central nervous 
system, epithelial cells, hematopoietic cells, osteoblasts, and osteoclasts.37 Pyk2 has 
been demonstrated in vitro to be a positive modulator of osteoclast activity.38 Studies 
have demonstrated that Pyk2 is necessary for both osteoclast function and bone 
resorption.39 Mice lacking the PTK2 gene (Pyk2 -/-) show impairment of osteoclast 
function and high bone mass.39 Additionally, Pyk2 has been demonstrated to play a 
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role in megakaryocyte mediated osteoblast proliferation.40 More recent studies have 
shown Pyk2 functions as a negative regulator of osteoblast mineralization, 
proliferation, and differentiation.41 Buckbinder and colleagues demonstrated that 
Pyk2-/- mice exhibit enhanced osteoblast activity, which contributes to bone gain in 
these mice.38, 42  In addition, Bruzzaniti and colleagues demonstrated that osteoblasts 
lacking Pyk2 show increased ALP activity, mineral deposition and migration.41 
PF-431396, a chemical inhibitor against the tyrosine kinases FAK and Pyk2, 
was found to increase bone mass in ovariectomized mice, suggesting inhibition of 
these molecules have bone anabolic applications. The half-maximal inhibitory 
concentration (IC50) of PF-431396 to FAK and Pyk2 are 2 nM and 11 nM, 
respectively.43 Oral administration of PF-562271, an inhibitor of both FAK (IC50 of 
1.5 nM) and Pyk2 (IC50 of 14 nM), was shown to restore tumor related bone loss in 
murine models.44, 45 Published studies from Dr. Bruzzaniti’s laboratory demonstrated 
that a newer Pyk2-targeted inhibitor, PF-4618433 (PF-46), promoted the proliferation 
and osteogenic differentiation of murine bone marrow-derived stromal osteoblasts.46 
PF-46 is a Pyk2-targeted inhibitor without significant inhibitory effect against FAK.46 
PF-46 is a synthetic organic compound, and its chemical structure is shown in Figure 
1.47 
One of the main challenges with REPs is predictable continued growth of root 
dentin in both length and width.14 PF-46, an inhibitor of Pyk2, has already been 
shown to promote osteoblast function and inhibit osteoclasts, thereby increasing 
mineralized bone tissue.46 Due to the need for formation of mineralized hard tissue in 
both osteogenesis and dentinogenesis, it is possible that PF-46 can also promote the 
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formation of mineralized tissue from DPSCs, which can be useful for REPs.48, 49 
Therefore, the aims of this study were to evaluate the effects of PF-46 on the 
proliferation and osteogenic differentiation of human DPSCs. The results of these 
studies will give insight into whether a Pyk2 inhibitor could have potential 
applications for endodontic regeneration. The investigation of PF-46 could potentially 
lead to applications in regeneration of the pulp-dentin complex. 
 
OBJECTIVE 
The purpose of this study was to investigate the effect of a Pyk2 inhibitor, PF-46, 
on the proliferation, differentiation, and mineralization of human DPSCs. 
 
NULL HYPOTHESIS 
 DPSCs grown in the presence of PF-46 will show no difference in proliferation, 
differentiation, and/or mineralization of DPSCs, compared to vehicle control. 
 
ALTERNATIVE HYPOTHESIS 
 DPSCs grown in the presence of PF-46 will show an increase in proliferation, 
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HISTORY OF ENDODONTICS 
 The earliest evidence of the practice of dentistry can be seen with the Indus 
Valley Civilization (IVC) around the year 7,000 B.C.50 9 adults from the IVC civilization 
were discovered in a prehistoric graveyard with evidence that molar crowns had been 
drilled upon using a primitive drill.50 In 5,000 B.C., the first reference of “tooth worms” 
can be found in a Sumerian text.51 The idea of tooth worms has been seen in many 
cultures, and it was believed that these tooth worms caused caries, periodontitis, and 
tooth-related pain.51 The earliest known dental practitioner was an Egyptian named Hesy-
Re around 2,500 B.C., and his tomb was inscribed with “the greatest of those who dealt 
with teeth.”52 
 Pierre Fauchard, a French surgeon considered as the “father of modern dentistry”, 
published The Surgeon Dentist, A Treatise on Teeth.52 This is considered the first book to 
detail the comprehensive practice of dentistry including anatomy and function, operative 
and restorative techniques, and denture construction.52-55 Fauchard also described aspects 
of endodontics such as pus drainage from pulp chambers, pulp extirpation, leaving teeth 
open, and obturating teeth with a metal foil.54, 55 
 In more modern times, the focal infection theory was gaining popularity and was 
introduced to dentistry. In 1925, Weston Price argued that bacteria within dentinal 
tubules could spread from the root canal system and cause disease elsewhere in the 
body.56 This work was influential in many practitioners to recommend extraction of teeth 
with necrotic pulps. Later work by several authors refuted the focal infection theory. In 
1937, Logan argued that the mere presence of microorganisms did not automatically 
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mean an infection was present.57, 58 The research of Fish, who is known for the “zones of 
Fish”, also refuted the focal infection theory.59 
 In 1943, 20 individuals including Dr. Harry Johnston met in Chicago for a 
meeting, and the American Association of Endodontics (AAE) was founded.58 At this 
meeting, the group discussed and formed standards of endodontic treatment.60 The term 
“endodontics” was chosen at this meeting by combining two Greek words, “endon” 
meaning “within” and “ho dontas” meaning “a tooth.”61 A little over a decade later in 
1956, the American Board of Endodontics was formed and recognized by the ADA 
Education Council.61 In 1963, with over 200 American dentists limiting their practice to 
endodontics, the ADA officially recognized endodontics as a dental specialty.60 In 1965, 
the first endodontic specialists became board certified.61 
 
THEORY OF ENDODONTICS 
 In 1965, Kakehashi et al. published a research paper that became a bedrock of 
future endodontic research.62 This study compared the pulp and periapical status of 
gnotobiotic rats to normal rats that had pulp chambers mechanically exposed. The 
gnotobiotic rats showed no evidence of disease, whereas normal rats developed pulp 
necrosis with apical periodontitis. This study showed that bacteria is the primary 
etiologic agent of periapical disease.62 
 Subsequent research supported the findings of Kakehashi. A study by Moller in 
1981 compared the periapical response of pulp chambers that were maintained bacteria-
free compared to pulp chambers that were allowed to be infected by the oral flora.63 
Moller’s work showed that necrotic and infected pulps lead to apical periodontitis, 
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whereas non-infected pulps did not develop apical periodontitis. In 1976, Sundqvist’s 
thesis also showed that teeth with necrotic pulps and apical periodontitis contained a 
variety of microorganisms including many anaerobes.2 
 This work that showed bacteria as the primary etiology of apical periodontitis led 
to the modern paradigms of endodontic treatment. Based upon these research studies, 
Grossman outlined his 13 fundamental principles of endodontic treatment:64 
1. Aseptic technique 
2. Instrument retention within the root canal system 
3. Instruments should never be forced apically 
4. Enlarging the canal space from its original size to accommodate obturation 
material 
5. Continuous irrigation with an antiseptic throughout treatment 
6. Irrigation solution should remain within the canal space 
7. Fistulas do not require a special protocol 
8. Negative culture should be confirmed prior to obturation of the root canal 
9. Obturation should include a hermetic seal of the root canal system 
10. Obturation material should not be irritating to tissues 
11. Alveolar abscess should be adequately drained 
12. Injections should be avoided into infectious areas 
13. Surgical treatment may be required for proper healing 
At the same time, Schilder introduced his obturation technique that involved the 
vertical compaction of warm gutta percha.65 He advocated this obturation method, as it 
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creates a three-dimensional fill of the root canal system including possible accessory 
canals. 
 
TREATMENT OF IMMATURE PERMANENT TEETH WITH PULP NECROSIS 
 The treatment of an immature permanent tooth with pulp necrosis presents 
multiple challenges to clinicians. These clinical challenges include the presence of an 
open apex, managing the root canal infection, and the presence of thin root walls.6 The 
open apex makes adequate irrigation and obturation a challenge. Because of the thin root 
walls of immature teeth, one must rely heavily on irrigants and intracanal medicaments 
for adequate disinfection of the root canal space rather than mechanical debridement of 
the canal.6 Furthermore, the thin root walls and shortened roots make these teeth more 
prone to fracture, and they can present a restorative challenge for clinicians.6 Potential 
treatment options of an immature permanent tooth with pulp necrosis include no 
treatment, extraction, apexification, or REPs.8, 14 
 The traditional apexification procedure aimed to create a hard tissue barrier at the 
apical-most extent of the root canal to facilitate adequate obturation of the tooth.66 This 
was done by first disinfecting the root canal system using a combination of diluted 
sodium hypochlorite (NaOCl) (~0.5%) and light hand filing.67 Next, the canal is filled 
with calcium hydroxide paste that extends into contact with the apical soft tissue, and a 
well-sealed coronal restoration is placed.12 Patients are periodically recalled at 3-month 
intervals to assess for washout of calcium hydroxide and to verify if a hard tissue barrier 
has formed. Following formation of the hard tissue barrier, the tooth can be obturated as 
usual.67 The more modern approach to apexification involves the use of a bioceramic 
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barrier technique. Following canal disinfection, a barrier (e.g., CollaTape) is pushed 
beyond the apex and a bioceramic such as mineral trioxide aggregate (MTA) is packed in 
the apical extent of the root canal system.68 After setting of the bioceramic, the remaining 
canal is obturated. Jeeruphan showed that MTA apexification technique can be 
performed successfully and with improved outcomes compared to calcium hydroxide 
apexification.5 
 An alternative treatment option to preserve immature permanent teeth with pulp 
necrosis is a REP. Like apexification procedures, REPs rely on initial disinfection of the 
canal space. In contrast to apexification, REPs aim to regenerate the pulp-dentin complex 
following disinfection rather than simply obturating the canal space.20 In theory, REPs 
have several distinct advantages when compared to apexification. By regenerating the 
pulp-dentin complex, a tooth can experience continued growth of the root in both length 
and width.5, 69 An outcome study compared REPs to apexification, and the authors found 
that REPs significantly increased root length and width compared to apexification 
procedures.5 
 Despite these advantages of REPs, there are still multiple challenges to be 
addressed. Ong published a recent systematic review and meta-analysis that included a 
quantitative assessment of root development in immature permanent teeth with necrotic 
pulps that underwent REPs.70 The authors found that pooled rates of root lengthening, 
root thickening, and apical closure were 77.3%, 90.6%, and 79.1% respectively.70 
However if 20% radiographic changes were used as a cutoff point, there were only 16.1% 
root lengthening and 39.8% root thickening.70 These results show that although high rates 
of root thickening and apical closure can be reported in studies, these changes are not 
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necessarily clinically significant in many cases. When a cutoff threshold of 20% change 
is applied, then the rates of root lengthening and thickening decrease significantly. 
Results of this and other studies show that the attainment of clinically significant and 
predictable root thickening and lengthening can be elusive to achieve with REPs.70, 71 
 REPs aim to regenerate the pulp-dentin complex, but it is unclear exactly what 
type of tissue is formed during REPs. A systematic review investigated the histology of 
REPs performed in animal studies, and this review found that none of the regeneration 
protocols resulted in the predictable formation of a true pulp-dentin complex.72 Other 
studies have shown root formation of a combination of cementum-like tissue, bone-like 
tissue, and dentin-like tissue.14, 72, 73 These studies call into question if true regeneration is 
occurring or if it would be better referred to as repair.74 
 
CLINICAL CONSIDERATIONS FOR REPs 
 On 4/1/2018, the AAE published the following guidelines for clinical 
considerations for a REP:75 
Case Selection 
• Tooth with necrotic pulp and an immature apex. 
• Pulp space not needed for post/core, final restoration. 
• Compliant patient/parent. 
• Patient not allergic to medicaments and antibiotics necessary to complete 
procedure (ASA 1 or 2). 
Informed Consent 
• Two (or more) appointments. 
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• Use of antimicrobial(s). 
• Possible adverse effects: staining of crown/root, lack of response to treatment, 
pain/infection. 
• Alternatives: MTA apexification, no treatment, extraction (when deemed non-
salvageable). 
• Permission to enter information into AAE database (optional). 
First Appointment 
• Local anesthesia, dental dam isolation and access. 
• Copious, gentle irrigation with 20 mL NaOCl using an irrigation system that 
minimizes the possibility of extrusion of irrigants into the periapical space (e.g., 
needle with closed end and side-vents, or EndoVac). Lower concentrations of 
NaOCl are advised (1.5% NaOCl, 20 mL/canal, 5 min) and then irrigated with 
saline or ethylenediaminetetraacetic acid (EDTA) (20 mL/canal, 5 min), with 
irrigating needle positioned about 1 mm from root end, to minimize cytotoxicity 
to stem cells in the apical tissues. 
• Dry canals with paper points. 
o Place calcium hydroxide or low concentration of triple antibiotic paste. If 
the triple antibiotic paste is used: 
 Consider sealing pulp chamber with a dentin bonding agent (to 
minimize risk of staining) and 
 Mix 1:1:1 ciprofloxacin: metronidazole: minocycline to a final 
concentration of 1-5 mg/mL. Triple antibiotic paste without 
minocycline paste or substitution of minocycline for other 
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antibiotic (e.g., clindamycin; amoxicillin; cefaclor) is another 
possible alternative as root canal disinfectant. Clinicians should be 
aware that studies have been done using higher concentrations of 
TAP/DAP, but a recommendation to a higher concentration can’t 
be made at this time due to limited studies. 
• Deliver into canal system via syringe. 
• If triple antibiotics is used, ensure that it remains below CEJ (minimize crown 
staining). 
• Seal with 3-4 mm of a temporary restorative material such as Cavit, IRM, glass-
ionomer or another temporary material. Dismiss patient for 1-4 weeks. 
Second Appointment (1-4 weeks after 1st visit) 
• Assess response to initial treatment. If there are signs/symptoms of persistent 
infection, consider additional treatment time with antimicrobial, or alternative 
antimicrobial. 
• Anesthesia with 3% mepivacaine without vasoconstrictor, dental dam isolation. 
• Copious, gentle irrigation with 20 mL of 17% EDTA. 
• Dry with paper points. 
• Create bleeding into canal system by over-instrumenting (endo file, endo 
explorer) (induce by rotating a pre-curved K-file at 2 mm past the apical foramen 
with the goal of having the entire canal filled with blood to the level of the 
cemento-enamel junction). An alternative to creating of a blood clot is the use of 
platelet-rich plasma, platelet-rich fibrin, or autologous fibrin matrix. 
• Stop bleeding at a level that allows for 3-4 mm of restorative material. 
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o Place a resorbable matrix such as CollaPlug, CollaCote, or CollaTape over 
the blood clot if necessary and white MTA as capping material. 
o A 3-4 mm layer of glass ionomer (e.g. Fuji IX, GC America, Alsip, IL) is 
flowed gently over the capping material and light-cured for 40 s. MTA has 
been associated with discoloration. Alternatives to MTA [such as 
bioceramics or tricalcium silicate cements (e.g., Biodentine, Septodont, 
Lancasted, PA, USA, EndoSequence BC RRM-Fast Set Putty, Brasseler, 
USA)] should be considered in teeth where there is an esthetic concern. 
 Anterior and premolar teeth: consider use of CollaTape/CollaPlug 
and restoring with 3 mm of a nonstaining restorative material 
followed by bonding a filled composite to the beveled enamel 
margin. 
 Molar teeth: consider use of CollaTape/CollaPlug and restoring 
with 3 mm of MTA, followed by RMGI, composite or alloy. 
Follow-up (6-, 12-, 24-months) 
• Clinical and radiographic exam: 
o No pain, soft tissue swelling or sinus tract (often observed between first 
and second appointments). 
o Resolution of apical radiolucency (often observed 6-12 months after 
treatment). 
o Increased width of root walls (this is generally observed before apparent 
increase in root length and often occurs 12-24 months after treatment). 
o Increased root length. 
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o Positive pulp vitality test response. 
o Recommended yearly follow-up after the first 2 years. 
o CBCT is highly recommended for initial evaluation and follow-up visits. 
• The degree of success of REPs is largely measured by the extent to which it is 
possible to attain primary, secondary, and tertiary goals: 
o Primary goal: the elimination of symptoms and the evidence of bony 
healing. 
o Secondary goal: Increased root wall thickness and/or increased root length 
(desirable, but perhaps not essential). 
o Tertiary goal: positive response to vitality testing (which if achieved, 
could indicate a more organized vital pulp tissue). 
 
PYK2 INHIBITOR: PF-46 
 As reviewed in the introduction section, PF-46 is a proline-rich tyrosine kinase 2 
inhibitor (Pyk2). Pyk2 is the second member of the FAK family of proteins, and it plays 
an important role in cell migration, polarization, proliferation, and cell survival.34, 35 
DPSCs and osteoblasts are both mineral-producing cells, and the Pyk2 pathway has been 
well-studied in both osteoblasts and osteoclasts. Buckbinder found that Pyk2 knockout 
mice exhibited enhanced differentiation and activity of osteoprogenitor cells, as do mice 
exposed to the specific Pyk2 inhibitor that was used in this study.38, 76, 77 Increased bone 
mass and inhibition of osteoclast activity was also observed in Pyk2 knockout mice.39 
Furthermore, Pyk2 inhibitors have been shown to negatively modulate osteoclast 
function and bone resorption activity.39, 78 Increased differentiation and mineralization of 
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osteoblasts has been observed when exposed to a specific Pyk2 inhibitor, PF-46.41, 46 
Because of the similarities between osteoblasts and odontoblasts, it is possible that PF-46 
can also promote the formation of mineralized tissue from DPSCs. This can potentially 
be useful for addressing obstacles of REPs such as predictable thickening and 


















 Group 1 – 0 μM PF-46 
 Group 2 – 0.1 μM PF-46 
 Group 3 – 0.3 μM PF-46 
 Group 4 – 0.6 μM PF-46 
 Groups 2, 3 and 4 represent the experimental treatment PF-46, whereas Group 1 
represents the negative (vehicle) control. Previous studies with osteoblasts showed 
positive assay results with concentrations up to 0.3 μM PF-46, so the concentrations 




 The project utilized both commercially available products as well as materials 
prepared in the lab as described in the methodology portion. Commercially available 
human DPSCs, collected from the pulp of extracted teeth, have been previously 
purchased from ALLCells and stored in liquid nitrogen (Alameda, CA, USA). 
• Cell culture 24-well plates (Alkali Scientific Inc. Cat: TP9024) 
• α modification of minimal essential media (HyClone Laboratories Inc., South 
Logan UT, USA) 
• 10% fetal bovine serum (Biowest, Kansas City, MO, USA) 
• 1% penicillin-streptomycin (Lonza, Allendale, NJ, USA) 
• 0.25% trypsin/EDTA (Life Technologies Corporation) 
• Phosphate buffered saline (HyClone Laboratories Inc., South Logan UT, USA) 
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• 1% (w/v) cetylpyridinium chloride (Sigma: C0732) 
• PF-4618433 (Adooq Bioscience: A13461-10) 
• ALP assay kit (Sigma Aldrich) 
• Alizarin Red-S (Sigma Aldrich) 
• Pierce BCA protein assay kit (Thermo Scientific: 23225) 




PREPARATION OF PF-46 TREATMENT GROUPS 
PF-46 treatment groups are prepared from a stock solution in dimethyl sulfoxide 
(DMSO) stored in -80°C. The stock solution is at a concentration of 44.9 mM. PF-46 was 
diluted in DMSO. For ease of manipulation 200 l of 2 mM PF-46 solution was created 
using 191.1 µL of DMSO and 8.9 µL of 44.9 mM PF-46 stock. This 2 mM stock solution 
was used to create treatment groups. 
 
HUMAN DENTAL PULP STEM CELLS CULTURE CONDITIONS 
 Human DPSCs were passaged once and stored in liquid nitrogen for later use. 
During each experiment, DPSCs were thawed and seeded in 10 cm2 culture dishes and 
cultured in  modification of minimum essential medium (-MEM) combined with 10% 
fetal bovine serum (FBS) plus penicillin/streptomycin. Previous experiments have 
provided optimal seeding densities for performance of the assays that were used in this 
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current project.79 Cells between 3 and 5 passages were seeded into 24-well plates at 
predetermined concentrations indicated below for each assay. 
The day following the seeding of DPSCs, 750 µL of fresh culture media was 
added to the bottom of the chamber. Depending on the treatment group, either 0, 0.1, 0.3, 
or 0.6 M of PF-46 was also present in the culture media. Only culture media was used 
as a negative control. Total media volume was 750 L/well. Culture media was replaced 
every 2-3 days with plates being incubated at 37°C in an incubator with 95% CO2/5% O2 
for the entirety of the experiment. 
 
CELL COUNTING 
 DPSCs were cultured in conditions described above. Cells were plated at 2 x 104 
cells/well. PF-46 was present in the cell culture media as described above. 4 days 
following exposure to the medicaments, cells were washed once in PBS and incubated 
for 5 minutes in the presence of trypsin. 500 L of cold media was added to each 
centrifuge tube, cells were spun at 1750 rpm for 5 minutes, and liquid was removed with 
a pipette. Cells were resuspended in 300 L of cold PBS, and direct cell counting was 
performed with a microscope and hemocytometer. Each treatment group was cultured in 
quadruplicates, and direct cell counting was performed once. 
 
MTS PROLIFERATION ASSAY 
 DPSCs were cultured in conditions described above. Cells were plated at 2 x 104 
cells/well. PF-46 was present in the cell culture media as described above. 1 day 
following exposure to the medicaments, cells were washed once in PBS and assayed 
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using CellTiter 96 aqueous non-radioactive cell proliferation assay kit from Promega. 
This assay measures the conversion of a tetrazolium compound [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium, inner salt; MTS] 
and the electron coupling reagent phenazine methosulfate (PMS) into a formazan 
product. This reaction occurs through dehydrogenase enzymes found in metabolically 
active cells. Reagent was removed at 3 hours with a read volume of 100 µL read in 
duplicates for every sample. Formazan product quantity was measured at 490 nm. Each 
treatment group was cultured in quadruplicates, and the assay was performed three times. 
 
ALKALINE PHOSPHATASE ACTIVITY ASSAY 
 Alkaline phosphatase (ALP) is an enzyme that plays an important role in bone 
mineralization, and the ALP assay is a useful quantitative assessment tool for 
differentiation of cells into mineral-forming cells.79 For the quantification of ALP 
activity, cells were plated at 4 x 104 cells/well in a 24-well plate. They were cultured in 
α-MEM plus 10% FBS and containing 50 mg/mL ascorbic acid and 10 mM β-glycerol 
phosphate to promote osteogenic differentiation for 14 days, with media changes every 2-
3 days. Following 14 days, cells were washed and lysed to be assayed for ALP activity. 
The ALP quantification protocol has been previously described.41 Cells were lysed with 
100 µL of modified radioimmunoprecipitation assay (mRIPA) buffer consisting of 50 
mM Tris-Cl pH 7.5, 150 mM NaCl, 1% NP-40, and 0.25% sodium deoxycholate. The 
buffer was supplemented with a protease inhibitor cocktail containing 10 µg/mL 
leupeptin hydrochloride, 10 µg/mL aprotinin, 10 µg/mL pepstatin, 1 mM PMSF, 1mM 
sodium fluoride, and 1mM sodium orthovanadate. Lysates were sonicated in 1.5 mL 
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centrifuge tubes for 5 minutes then spun at 13,000 rpm for 5 minutes prior to collecting 
the supernatant. 5 µL of cell lysate was assayed in triplicates in a 96-well plate. ALP 
substrate containing 2 mg/mL p-nitrophenyl phosphate in 1.5 M alkaline buffer was 
added to the lysates and then the mixture was incubated for 45 minutes at 37°C in a foil 
to protect the reaction from light. Lysis buffer was also assayed with the substrate to be 
used for background measurements. The reaction was stopped after 45 minutes by adding 
20 mM NaOH for a final volume of 200 µL. The ALP standard curve was calculated 
concurrently with the assay using serial dilutions of 4-nitrophenol and 20 mM NaOH to 
determine the ALP activity. Absorbance for the plate was read at 405 nm. ALP activity 
per individual sample was normalized through quantification of total protein content in 
each sample. Protein quantification was performed using the Pierce BCA protein assay 
kit and following the manufacture specifications. The final results were expressed as 
ALP activity per µg protein. Each treatment group was cultured in quadruplicates, and 
the assay was performed three times. 
 
QUANTITATIVE MINERAL DEPOSITION ASSAY 
 The quantitative mineral deposition assay is proportional to the amount of 
extracellular mineralized deposits.79 DPSCs were plated at 4 x 104 cells/well and cultured 
in α-MEM plus 10% FBS and containing 50 mg/mL ascorbic acid and 10 mM β-glycerol 
phosphate to provide an osteogenic environment, and stimulated with the PF-46 
concentrations described above. After 14 days, media was removed and cells were 
washed in PBS and fixed in 3.7% formaldehyde in PBS for 15 minutes. Quantitative 
analysis of the mineral deposition was performed as previously described with Alizarin 
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Red-S, a calcium binding stain.41 The cells were then washed for 15 minutes in PBS. 
Following aspiration of PBS, 500 µL of 40 mM Alizarin Red-S Solution at a pH 4.2 was 
added to each well on the plate. The plate was then placed on a shaker for 30 minutes. 
Following treatment with the stain, cells were washed a total of 3 times with tap water to 
remove any residual stain and again with PBS for 15 minutes on the shaker. Then 500 µL 
of 1% (w/v) cetylpyridinium chloride (CPC) was added to each well to extract 
extracellularly bound Alizarin Red-S stain. A standard curve was created using a serial 
dilution by using 1% CPC and 40 mM Alizarin Red-S and the calcium concentrations 
were determined based on Alizarin binding capabilities to calcium (2 mol calcium per 1 
mol dye). Samples were read in triplicate at 200 µL in a 96-well plate in a 
spectrophotometer at 562 nm. Each treatment group was cultured in quadruplicates, and 
the assay was performed three times. 
 
SAMPLE SIZE AND STATISTICAL ANALYSIS 
 Experiments were performed in triplicate or quadruplicate, and repeated 2-4 
times, with similar results.  Graphs demonstrate mean ± SEM for representative 
experiments for each assay. Differences between treatment groups were analyzed by a 
one-way analysis of variance (ANOVA) followed by pair-wise tests conducted using 
Tukey’s multiple comparisons procedure. The ANOVAs did not assume homogeneous 
variances. A 5% significance level was used for all tests. Analyses were performed using 
SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA). George Eckert assisted with the 
statistical analysis (Department of Biostatistics and Health Data Science, Indiana 















THE EFFECT OF PF-46 ON DPSC NUMBER  
 Direct cell counting of DPSCs was performed after cells were exposed to various 
concentrations of PF-46 for 4 days. The 0.6 μM PF-46 group had a statistically 
significant higher cell count when compared to 0 μM PF-46. Although not statistically 
significant, the 0.1 μM PF-46 and 0.3 μM PF-46 groups also displayed a higher cell count 
than 0 μM PF-46. The graph of results, shown in Figure 6, showed a trend of increasing 
cell count as the concentration of PF-46 increased up to 0.6 μM. There were no 
statistically significant differences between the groups that contained PF-46. The cell 
counting results are summarized in Tables 1 and 2. 
 
THE EFFECT OF PF-46 ON MTS PROLIFERATION ACTIVITY OF DPSCs 
 The MTS proliferation assay measures the metabolic activity of cells, and 
previous studies have shown that results of this assay are proportional to live number of 
cells.46 After culturing for 1 day and measuring MTS proliferation activity, no statistical 
differences were present when comparing the groups that contained PF-46 to the 0 μM 
PF-46 group. Although no significant differences were present, proliferation activity was 
generally higher in the groups that contained PF-46 compared to the 0 μM PF-46 group 
(Figure 7). There was also a trend of decreased proliferation activity as the concentration 
of PF-46 increased from 0.1 μM to 0.6 μM. The MTS proliferation activity results are 





THE EFFECT OF PF-46 ON ALP ACTIVITY OF DPSCs 
 The ALP assay measures ALP enzymatic activity per microgram of protein, 
which is an indicator of early differentiation of osteogenic cells.80 ALP activity was 
measured after culturing cells for 14 days with various concentrations of PF-46. All 3 
groups that contained PF-46 (0.1, 0.3 and 0.6 μM) had ALP activity levels that were 
higher than 0 μM PF-46, and these differences were statistically significant. Although 
there were no significant differences between groups that contained PF-46, ALP activity 
increased as PF-46 concentration increased from 0.1 μM to 0.6 μM (Figure 8). The ALP 
activity results are summarized in Tables 1 and 4. 
 
THE EFFECT OF PF-46 ON MINERAL DEPOSITION BY DPSCs 
 Mineral deposition of DPSCs was measured after cells were exposed to various 
concentrations of PF-46 for 14 days. The 0.6 μM PF-46 group had significantly higher 
mineral deposition when compared to 0 μM PF-46. Although not statistically significant, 
the 0.1 μM PF-46 and 0.3 μM PF-46 groups also displayed higher mineral deposition 
than 0 μM PF-46. The graph of results in Figure 9 showed a trend of increasing mineral 
deposition as the concentration of PF-46 increased up to 0.6 μM. There were no 
statistically significant differences between the groups that contained PF-46. The mineral 
































































FIGURE 6: Cell counting results showing the mean of 4 wells per treatment group with 
standard error of the mean (SEM). An asterisk shows statistical significance compared to 









FIGURE 7: MTS proliferation assay results showing the mean of 4 wells per treatment 
group with SEM. There was no statistically significant difference for 0.1, 0.3 and 0.6 μM 










FIGURE 8: ALP assay results showing the mean of 4 wells per treatment group with 










FIGURE 9: Mineral deposition assay results showing the mean of 4 wells per treatment 










 Summary of results for proliferation, ALP activity, and mineral deposition 
Outcome Group N Mean SD SE Min Max 
Cell counting 
(cells/mL (104)) 
0 μM PF-46 3 33.67 8.10 4.68 28.50 43.00 
0.1 μM PF-46 4 40.25 9.75 4.87 26.75 49.75 
0.3 μM PF-46 2 45.50 5.30 3.75 41.75 49.25 




0 μM PF-46 5 0.242 0.062 0.028 0.172 0.290 
0.1 μM PF-46 4 0.324 0.008 0.004 0.318 0.335 
0.3 μM PF-46 4 0.314 0.006 0.003 0.306 0.319 
0.6 μM PF-46 4 0.289 0.015 0.007 0.267 0.300 
ALP activity 
(nM/mL/μg) 
0 μM PF-46 4 2.80 0.25 0.13 2.54 3.13 
0.1 μM PF-46 4 5.17 1.15 0.58 4.25 6.85 
0.3 μM PF-46 4 5.22 0.93 0.46 4.52 6.58 
0.6 μM PF-46 4 6.81 0.87 0.44 6.02 7.84 
Mineral deposition 
(μg/mL Ca2+) 
0 μM PF-46 4 14.51 1.87 0.93 12.65 16.14 
0.1 μM PF-46 4 17.99 1.58 0.79 16.43 19.62 
0.3 μM PF-46 4 18.30 2.30 1.15 15.47 20.32 












Pair-wise comparisons – Cell counting 
Result p-value 
0 μM PF-46 & 0.1 μM PF-46 n.s. 0.861 
0 μM PF-46 & 0.3 μM PF-46 n.s. 0.343 
0 μM PF-46 < 0.6 μM PF-46 0.025 
0.1 μM PF-46 & 0.3 μM PF-46 n.s. 0.907 
0.1 μM PF-46 & 0.6 μM PF-46 n.s. 0.189 












Pair-wise comparisons – MTS proliferation 
Result p-value 
0 μM PF-46 & 0.1 μM PF-46 n.s. 0.063 
0 μM PF-46 & 0.3 μM PF-46 n.s. 0.122 
0 μM PF-46 & 0.6 μM PF-46 n.s. 0.485 
0.1 μM PF-46 & 0.3 μM PF-46 n.s. 0.243 
0.1 μM PF-46 > 0.6 μM PF-46 0.006 












Pair-wise comparisons – ALP activity 
Result p-value 
0 μM PF-46 < 0.1 μM PF-46 0.009 
0 μM PF-46 < 0.3 μM PF-46 0.001 
0 μM PF-46 < 0.6 μM PF-46 0.000 
0.1 μM PF-46 & 0.3 μM PF-46 n.s. 1.000 
0.1 μM PF-46 & 0.6 μM PF-46 n.s. 0.207 












Pair-wise comparisons – Mineral deposition 
Result p-value 
0 PF-46 & 0.1 μM PF-46 n.s. 0.079 
0 μM PF-46 & 0.3 μM PF-46 n.s. 0.129 
0 μM PF-46 < 0.6 μM PF-46 0.001 
0.1 μM PF-46 & 0.3 μM PF-46 n.s. 0.999 
0.1 μM PF-46 & 0.6 μM PF-46 n.s. 0.233 

















 This study investigated the proliferation, differentiation, and mineral deposition 
by DPSCs when exposed to various concentrations of the Pyk2 inhibitor, PF-46. 
Depending on the assay, cells were exposed to 0, 0.1 μM, 0.3 μM, or 0.6 μM PF-46, and 
cultured for either 1, 4 or 14 days, and then assayed for proliferation assay, cell growth, 
ALP activity and mineral deposition, respectively. 
 The results from direct cell counting following a 4-day incubation period with 
various concentrations of PF-46 are summarized in Figure 6 and Tables 1 and 2. When 
compared to 0 μM PF-46, the 0.6 μM PF-46 group had a statistically significant higher 
cell count. Although not statistically significant, the 0.1 μM and 0.3 μM PF-46 groups 
also had a higher cell count number compared to 0 μM PF-46. The graph in Figure 6 
showed a general trend of increasing cell count as PF-46 was increased up to 0.6 μM PF-
46. We also performed an MTS assay to examine DPSC proliferation. The MTS 
proliferation assay was performed following a 1-day incubation period with the different 
PF-46 concentrations, and the results of this assay are summarized in Figure 7 and Tables 
1 and 3. There were no statistically significant differences when comparing the 0 μM PF-
46 group to the other 3 groups, but the groups that contained PF-46 generally had an 
increased values for the proliferation assay. Interestingly, the only statistically significant 
difference between groups was a higher response for the 0.1 μM PF-46 compared to 0.6 
μM PF-46. The MTS proliferation assay is a measure of cellular mitochondrial metabolic 
activity, and this is generally proportional to cell number. However, the 0.6 μM PF-46 
group had the highest cell count from direct counting. It is possible that the 0.6 μM PF-46 
group had already gone through the peak of its growth phase when the MTS proliferation 
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assay was performed, and this would explain its higher cell count but lower response to 
the MTS proliferation assay. 
  The results from the ALP assay following a 14-day incubation period with 
various concentrations of PF-46 are summarized in Figure 8 and Tables 1 and 4. All 3 
groups that contained PF-46 (0.1, 0.3, and 0.6 μM) had a statistically significant higher 
ALP activity compared to 0 μM PF-46. Although there was no statistical difference 
among the groups that contained PF-46, Figure 8 shows a trend of increasing ALP 
activity as the concentration of PF-46 increased up to 0.6 μM. The ALP enzyme plays an 
important role in bone mineralization, and ALP activity levels correlate with 
differentiation into mineral-producing cells. The results of this assay show that the 0.1, 
0.3, and 0.6 μM PF-46 groups had increased differentiation into a mineral-producing cell 
line. 
 The mineral deposition assay was the final assay performed, and these values 
were obtained after 14 days of incubation with the various concentrations of PF-46. 
Figure 9 and Tables 1 and 5 show a summary of the mineral deposition data. The 0.6 μM 
PF-46 group had a statistically significant higher mineral deposition compared to 0 μM 
PF-46, and there were no other statistically significant differences between groups. Also, 
the graph in Figure 9 demonstrates that mineral deposition had an increasing trend as the 
concentration of PF-46 increased up to 0.6 μM. In the formation of hard tissue, mineral 
deposition is one of the final steps. The results of this assay show that the addition of PF-
46, specifically at a concentration of 0.6 μM, increased mineral deposition compared to 
no PF-46. 
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 To summarize the results, there was a general dose-dependent increase in cell 
count, ALP activity, and mineral deposition as the concentration of PF-46 increased up to 
0.6 μM. Furthermore, the 0.6 μM PF-46 group had a statistically significant higher cell 
count, ALP activity, and mineral deposition compared to 0 μM PF-46. The higher cell 
count with 0.6 μM PF-46 indicates that this concentration caused in increased 
proliferation. Similarly, the increased ALP activity and mineral deposition of 0.6 μM PF-
46 indicates that this concentration increased differentiation and mineralization of 
DPSCs. Thus, the null hypothesis that there would be no difference in proliferation, 
differentiation, and/or mineralization of DPSCs grown in the presence of PF-46 
compared to only cell culture media was rejected. 
 To the authors’ knowledge, no previous study has investigated the effects of 
modulating the Pyk2 pathway on the function of DPSCs. However, the Pyk2 pathway has 
been studied previously in both osteoblasts and osteoclasts. Buckbinder and colleagues 
found that Pyk2 knockout mice enhanced differentiation and activity of osteoprogenitor 
cells, as does the Pyk2 inhibitor that was used in this study.38 Gil-Henn et al. also 
investigated Pyk2 knockout mice, and they found that Pyk2 knockout osteoclast function 
was inhibited due to impaired microtubule-dependent podosome organization.39, 41, 78 
More recently, Posritong and colleagues researched the effects of a PF-46 loaded into a 
hydrogel on osteoblast activity and mineral deposition.46 This hydrogel containing PF-46 
promoted ALP activity and mineral deposition, and the response was most pronounced at 
a concentration of 0.1 μM PF-46.46 In contrast to this study that was performed with 
murine bone marrow stromal osteoblasts, our study showed the highest assay responses 
with a concentration of 0.6 μM PF-46.46 
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 One limitation of this study is that the highest tested concentration of PF-46, 0.6 
μM, produced the most favorable assay results for cell counting, differentiation and 
mineral deposition. This maximum value of 0.6 μM PF-46 was chosen based on the 
concentrations used previously in an osteoblast study which showed maximum responses 
with a concentration of 0.1 μM PF-46.46 A future experiment that included even higher 
concentrations of PF-46 would be beneficial to determine the optimal concentration of 
PF-46. Also, extending the duration of the cultures to 21 days may also show more robust 
differences between the treatment groups and the negative vehicle control.  Several 
studies using osteoblasts has shown increased mineral deposition after 21 days.76 
Another limitation of this study is that it is unclear based upon the collected data 
if the DPSCs differentiated into an osteoblast-like or odontoblast-like lineage. There are 
previous studies that have investigated the histology of the regenerated pulp-dentin 
complex in vivo, and the results are variable. One case report stated that apical closure 
and the increase in root length and width were due to the deposition of cementum-like 
tissue without dentin.81 Other studies have shown root formation of a combination of 
cementum-like tissue, bone-like tissue, and dentin-like tissue.14, 72 It is difficult to identify 
odontoblast-like cells in vitro due to their lack of unique cellular markers and overlap 
with osteoblast-like cells. Dentin sialoprotein (DSP) is expressed by both odontoblast-
like and osteoblast-like cells, although DSP is expressed nearly 400 times greater in 
odontoblasts.82 Similarly, expression of the intermediate filament protein, nestin, has 
been suggested to be used to identify odontoblast-like cells.83, 84 In a future experiment, 
quantitative polymerase chain reaction or RNA-sequencing analyses of these and similar 
50 
genes can potentially be performed to elucidate clues as to whether the DPSCs are 
differentiating into more of an odontoblast-like or osteoblast-like cell type.85 
 External cervical resorption (ECR) is a challenging clinical entity to treat. Since 
Pyk2-deletion and Pyk2 inhibitors reduce osteoclast bone resorbing activity, Pyk2-
targeted therapies such as PF-46 theoretically might have a positive effect in arresting or 
reversing osteoclast activity in ECR lesions.86 Although not fully understood, it is 
believed that ECR develops from both an initiating factor and a stimulating factor.87 A 
common initiating factor can be local destruction of the normal PDL structure, such as 
gap in the cementoenamel junction that could allow granulation tissue to reach the 
dentin.87 For ECR to continue, a stimulating factor such as bacteria or continuous 
mechanical force is also required.87 When exposed to dentin and stimulated, osteoclasts 
resorb dentin which can subsequently be replaced with new bone formation by 
osteoblasts.88 Inhibiting Pyk2 has been shown in previous studies to promote osteoblast 
activity and inhibit osteoclast activity.46 Because of this, a potential future project could 















SUMMARY AND CONCLUSIONS 
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In conclusion, the null hypothesis was rejected based on the results of this study. 
When compared to the vehicle control (0 μM PF-46), the 0.6 μM PF-46 group had a 
significantly higher cell count, ALP activity and mineral deposition. Also, the 0.1 and 0.3 
μM PF-46 groups had significantly higher ALP activity compared to the 0 μM PF-46 
group. There was a general concentration-dependent increase in assay results as the 
concentration of PF-46 increased up to 0.6 μM. A future study that includes higher 
concentrations of PF-46 would be beneficial to determine the optimal concentration of 
PF-46. Although further research is needed, these results suggest that strategies that target 
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Introduction: Regenerative endodontic procedures are an effective treatment 
option for immature teeth with infected necrotic pulps to allow for healing and potential 
continued root development, yet challenges to ideal treatment outcomes remain. 
Consistent development of root length and width of dentin remains a challenge, as does 
development of the pulp-dentin complex. Previous in vitro studies have assessed the role 
of different growth factors and bioactive molecules in combination with scaffolds to 
potentially facilitate continued development of the pulp-dentin complex using dental pulp 
stem cells (DPSCs). The proline-rich tyrosine kinase 2 (Pyk2) is linked with osteoblast 
activity and the regulation of bone mass.  Further, the Pyk2 inhibitor PF-4618433 (PF-
46) has been shown in previous studies to enhance osteoblast activity and mineral 
deposition in vitro. However, whether Pyk2 targeting promotes the osteogenic 
differentiation of DPSCs remains unknown. 
Objective: The purpose of this study was to investigate the effect of a Pyk2 
inhibitor, PF-46, on the proliferation, differentiation, and mineralization of human 
DPSCs. 
Materials and Methods: Human DPSCs were cultured in 24-well plates with α-
MEM with 10% FBS, and containing 0 μM (vehicle control) or 0.1 μM, 0.3 μM, or 0.6 
μM PF-46. Fresh media and treatments were replaced every 2-3 days. After 1 day 
incubation, cytotoxic effects were evaluated by using an MTS proliferation assay. After 4 
days of treatment, direct cell counting was performed. To induce osteogenic 
differentiation, ascorbic acid and β-glycerol phosphate were added to the culture media 
and the DPSCs were cultured with PF-46 for 14 days. Then, an alkaline phosphatase 
(ALP) assay and mineral deposition assay were performed. Differences between 
64 
treatment groups were analyzed by a one-way ANOVA followed by pair-wise tests 
conducted using Tukey’s multiple comparisons procedure with a 5% significance level. 
Results: The 0.6 μM PF-46 group had a significantly higher cell count, ALP 
activity and mineral deposition when compared to 0 μM PF-46. The 0.1 and 0.3 μM PF-
46 groups also had significantly higher ALP activity compared to the 0 μM PF-46 group 
after 14 days of incubation. There was a general trend of increased differentiation and 
mineral deposition as the concentration of PF-46 increased from 0.1 μM to 0.6 μM. 
Conclusion: There was a general concentration-dependent increase in cell count, 
differentiation, and mineral deposition by human DPSCs as the concentration of PF-46 
increased from 0 μM up to 0.6 μM, with the highest activity observed with 0.6 μM PF-
46. Although further research is needed, these results suggest that strategies that target 
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